Zealand Pharma A/S (CPH:ZEAL)
470.10
+0.50 (0.11%)
Dec 17, 2025, 12:25 PM CET
Zealand Pharma Revenue
Zealand Pharma had revenue of 49.57M DKK in the quarter ending September 30, 2025, with 1,022.74% growth. This brings the company's revenue in the last twelve months to 9.16B, up 11,809.72% year-over-year. In the year 2024, Zealand Pharma had annual revenue of 62.69M, down -81.71%.
Revenue (ttm)
9.16B
Revenue Growth
+11,809.72%
P/S Ratio
3.61
Revenue / Employee
20.81M
Employees
335
Market Cap
33.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.69M | -280.10M | -81.71% |
| Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
| Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
| Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
| Dec 31, 2020 | 192.00M | 150.67M | 364.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 315.60B |
| Coloplast | 27.87B |
| Genmab | 24.48B |
| H. Lundbeck | 24.08B |
| Demant | 22.59B |
| GN Store Nord | 17.12B |
| Bavarian Nordic | 6.89B |
| ALK-Abelló | 6.08B |
Zealand Pharma News
- 1 day ago - Zealand Pharma A/S (ZLDPF) Analyst/Investor Day Transcript - Seeking Alpha
- 5 days ago - Zealand Pharma A/S (ZLDPF) Analyst/Investor Day - Slideshow - Seeking Alpha
- 5 days ago - Zealand Pharma increases its share capital as a result of the exercise of employee warrants - GlobeNewsWire
- 5 days ago - Zealand Pharma (ZLDPF) Partners with OTR Therapeutics for Metabolic Disease Therapies - GuruFocus
- 6 days ago - Zealand Pharma Unveils Strategy To Lead In Metabolic Health - Nasdaq
- 6 days ago - Zealand Pharma to accelerate drug development for obesity, metabolic disease - Reuters
- 6 days ago - Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health - GlobeNewsWire
- 6 days ago - Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases - GlobeNewsWire